{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:03:22Z","timestamp":1785506602502,"version":"3.56.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s11523-026-01225-0","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T05:57:15Z","timestamp":1781503035000},"page":"459-474","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chimeric Antigen Receptor-T Cell Therapy for Pediatric and Young Adult Primary Central Nervous System Tumors: A Systematic Review of Early Phase Clinical Trials with a Focus on Diffuse Midline Glioma"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3637-5033","authenticated-orcid":false,"given":"Sai","family":"Sanikommu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro N.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashar","family":"Dawoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khushi H.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Vazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish H.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor M.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"issue":"10","key":"1225_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16101814","volume":"16","author":"M Mandorino","year":"2024","unstructured":"Mandorino M, Maitra A, Armenise D, et al. Pediatric diffuse midline glioma H3K27-altered: from developmental origins to therapeutic challenges. Cancers (Basel). 2024;16(10):1814. https:\/\/doi.org\/10.3390\/cancers16101814.","journal-title":"Cancers (Basel)"},{"issue":"13","key":"1225_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cells13131122","volume":"13","author":"LF Nonnenbroich","year":"2024","unstructured":"Nonnenbroich LF, Bouchal SM, Millesi E, Rechberger JS, Khatua S, Daniels DJ. H3K27-Altered diffuse midline glioma of the brainstem: from molecular mechanisms to targeted interventions. Cells. 2024;13(13):1122. https:\/\/doi.org\/10.3390\/cells13131122.","journal-title":"Cells"},{"issue":"10","key":"1225_CR3","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/nrc3811","volume":"14","author":"C Jones","year":"2014","unstructured":"Jones C, Baker SJ. Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma. Nat Rev Cancer. 2014;14(10):651\u201361. https:\/\/doi.org\/10.1038\/nrc3811.","journal-title":"Nat Rev Cancer"},{"key":"1225_CR4","doi-asserted-by":"publisher","first-page":"1082062","DOI":"10.3389\/fonc.2022.1082062","volume":"12","author":"SG Vallero","year":"2022","unstructured":"Vallero SG, Bertero L, Morana G, et al. Pediatric diffuse midline glioma H3K27- altered: a complex clinical and biological landscape behind a neatly defined tumor type. Front Oncol. 2022;12:1082062. https:\/\/doi.org\/10.3389\/fonc.2022.1082062.","journal-title":"Front Oncol"},{"issue":"3","key":"1225_CR5","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1093\/neuonc\/noq199","volume":"13","author":"IF Pollack","year":"2011","unstructured":"Pollack IF, Stewart CF, Kocak M, et al. A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium. Neuro Oncol. 2011;13(3):290\u20137. https:\/\/doi.org\/10.1093\/neuonc\/noq199.","journal-title":"Neuro Oncol"},{"issue":"4","key":"1225_CR6","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1093\/neuonc\/noq205","volume":"13","author":"KJ Cohen","year":"2011","unstructured":"Cohen KJ, Heideman RL, Zhou T, et al. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children\u2019s Oncology Group. Neuro Oncol. 2011;13(4):410\u20136. https:\/\/doi.org\/10.1093\/neuonc\/noq205.","journal-title":"Neuro Oncol"},{"issue":"1","key":"1225_CR7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ijrobp.2009.04.031","volume":"77","author":"R Jalali","year":"2010","unstructured":"Jalali R, Raut N, Arora B, et al. Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys. 2010;77(1):113\u20138. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.04.031.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"18","key":"1225_CR8","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.1016\/j.ejca.2013.08.006","volume":"49","author":"S Bailey","year":"2013","unstructured":"Bailey S, Howman A, Wheatley K, et al. Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy\u2014results of a United Kingdom phase II trial (CNS 2007 04). Eur J Cancer. 2013;49(18):3856\u201362. https:\/\/doi.org\/10.1016\/j.ejca.2013.08.006.","journal-title":"Eur J Cancer"},{"issue":"7560","key":"1225_CR9","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature14432","volume":"523","author":"A Louveau","year":"2015","unstructured":"Louveau A, Smirnov I, Keyes TJ, et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015;523(7560):337\u201341. https:\/\/doi.org\/10.1038\/nature14432.","journal-title":"Nature"},{"issue":"9","key":"1225_CR10","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nri3265","volume":"12","author":"RM Ransohoff","year":"2012","unstructured":"Ransohoff RM, Engelhardt B. The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol. 2012;12(9):623\u201335. https:\/\/doi.org\/10.1038\/nri3265.","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"1225_CR11","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1084\/jem.20142290","volume":"212","author":"A Aspelund","year":"2015","unstructured":"Aspelund A, Antila S, Proulx ST, et al. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J Exp Med. 2015;212(7):991\u20139. https:\/\/doi.org\/10.1084\/jem.20142290.","journal-title":"J Exp Med"},{"issue":"2","key":"1225_CR12","doi-asserted-by":"publisher","first-page":"e70497","DOI":"10.1002\/mco2.70497","volume":"7","author":"X Guo","year":"2026","unstructured":"Guo X, Liu H, Song YJ, et al. Neuro-immune crosstalk: molecular mechanisms, biological functions, diseases, and therapeutic targets. MedComm (2020). 2026;7(2):e70497. https:\/\/doi.org\/10.1002\/mco2.70497.","journal-title":"MedComm (2020)"},{"issue":"3","key":"1225_CR13","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ccell.2017.02.009","volume":"31","author":"DF Quail","year":"2017","unstructured":"Quail DF, Joyce JA. The microenvironmental landscape of brain tumors. Cancer Cell. 2017;31(3):326\u201341. https:\/\/doi.org\/10.1016\/j.ccell.2017.02.009.","journal-title":"Cancer Cell"},{"issue":"6640","key":"1225_CR14","doi-asserted-by":"publisher","DOI":"10.1126\/science.abo7649","volume":"380","author":"G Castellani","year":"2023","unstructured":"Castellani G, Croese T, Peralta Ramos JM, Schwartz M. Transforming the understanding of brain immunity. Science. 2023;380(6640):eabo7649. https:\/\/doi.org\/10.1126\/science.abo7649.","journal-title":"Science"},{"issue":"26","key":"1225_CR15","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1707447.","journal-title":"N Engl J Med"},{"issue":"1","key":"1225_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1804980.","journal-title":"N Engl J Med"},{"issue":"8046","key":"1225_CR17","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","volume":"637","author":"M Monje","year":"2025","unstructured":"Monje M, Mahdi J, Majzner R, et al. Intravenous and intracranial GD2-CAR T cells for H3K27M(+) diffuse midline gliomas. Nature. 2025;637(8046):708\u201315. https:\/\/doi.org\/10.1038\/s41586-024-08171-9.","journal-title":"Nature"},{"issue":"4","key":"1225_CR18","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","volume":"30","author":"CE Brown","year":"2024","unstructured":"Brown CE, Hibbard JC, Alizadeh D, et al. Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. Nat Med. 2024;30(4):1001\u201312. https:\/\/doi.org\/10.1038\/s41591-024-02875-1.","journal-title":"Nat Med"},{"issue":"4","key":"1225_CR19","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","volume":"43","author":"B Du","year":"2025","unstructured":"Du B, Qin J, Lin B, Zhang J, Li D, Liu M. CAR-T therapy in solid tumors. Cancer Cell. 2025;43(4):665\u201379. https:\/\/doi.org\/10.1016\/j.ccell.2025.03.019.","journal-title":"Cancer Cell"},{"issue":"11","key":"1225_CR20","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1016\/j.ymthe.2020.09.015","volume":"28","author":"J Wagner","year":"2020","unstructured":"Wagner J, Wickman E, DeRenzo C, Gottschalk S. CAR T cell therapy for solid tumors: bright future or dark reality? Mol Ther. 2020;28(11):2320\u201339. https:\/\/doi.org\/10.1016\/j.ymthe.2020.09.015.","journal-title":"Mol Ther"},{"issue":"7903","key":"1225_CR21","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","volume":"603","author":"RG Majzner","year":"2022","unstructured":"Majzner RG, Ramakrishna S, Yeom KW, et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature. 2022;603(7903):934\u201341. https:\/\/doi.org\/10.1038\/s41586-022-04489-4.","journal-title":"Nature"},{"issue":"8","key":"1225_CR22","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1093\/neuonc\/noaf064","volume":"27","author":"J Gust","year":"2025","unstructured":"Gust J, Cole BL, Ronsley R, et al. Locoregional infusion of EGFR806-CAR T cells for recurrent or refractory pediatric CNS tumors: results of the completed BrainChild02 phase 1 clinical trial. Neuro Oncol. 2025;27(8):2170\u201381. https:\/\/doi.org\/10.1093\/neuonc\/noaf064.","journal-title":"Neuro Oncol"},{"issue":"3","key":"1225_CR23","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/s41591-024-03451-3","volume":"31","author":"NA Vitanza","year":"2025","unstructured":"Vitanza NA, Ronsley R, Choe M, et al. Intracerebroventricular B7\u2013H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial. Nat Med. 2025;31(3):861\u20138. https:\/\/doi.org\/10.1038\/s41591-024-03451-3.","journal-title":"Nat Med"},{"issue":"9","key":"1225_CR24","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1038\/s41591-021-01404-8","volume":"27","author":"NA Vitanza","year":"2021","unstructured":"Vitanza NA, Johnson AJ, Wilson AL, et al. Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis. Nat Med. 2021;27(9):1544\u201352. https:\/\/doi.org\/10.1038\/s41591-021-01404-8.","journal-title":"Nat Med"},{"issue":"8","key":"1225_CR25","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","volume":"3","author":"N Ahmed","year":"2017","unstructured":"Ahmed N, Brawley V, Hegde M, et al. HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial. JAMA Oncol. 2017;3(8):1094\u2013101. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0184.","journal-title":"JAMA Oncol"},{"issue":"23","key":"1225_CR26","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1200\/jco.23.02019","volume":"42","author":"FY Lin","year":"2024","unstructured":"Lin FY, Stuckert A, Tat C, et al. Phase I trial of GD2.CART cells augmented with constitutive interleukin-7 receptor for treatment of high-grade pediatric CNS tumors. J Clin Oncol. 2024;42(23):2769\u201379. https:\/\/doi.org\/10.1200\/jco.23.02019.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1225_CR27","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1186\/s12967-025-06523-1","volume":"23","author":"J Gu","year":"2025","unstructured":"Gu J, Li J, Xu Y, et al. Preliminary exploration of PSMA CAR-T combined with GD2 CAR-T for the treatment of refractory\/relapsed gliomas. J Transl Med. 2025;23(1):591. https:\/\/doi.org\/10.1186\/s12967-025-06523-1.","journal-title":"J Transl Med"},{"issue":"4","key":"1225_CR28","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625\u201338. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"1225_CR29","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41591-023-02276-w","volume":"29","author":"J Mahdi","year":"2023","unstructured":"Mahdi J, Dietrich J, Straathof K, et al. Tumor inflammation-associated neurotoxicity. Nat Med. 2023;29(4):803\u201310. https:\/\/doi.org\/10.1038\/s41591-023-02276-w.","journal-title":"Nat Med"},{"issue":"5","key":"1225_CR30","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","volume":"30","author":"SJ Bagley","year":"2024","unstructured":"Bagley SJ, Logun M, Fraietta JA, et al. Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results. Nat Med. 2024;30(5):1320\u20139. https:\/\/doi.org\/10.1038\/s41591-024-02893-z.","journal-title":"Nat Med"},{"issue":"15","key":"1225_CR31","doi-asserted-by":"publisher","first-page":"e534","DOI":"10.1016\/s1470-2045(15)00088-1","volume":"16","author":"H Okada","year":"2015","unstructured":"Okada H, Weller M, Huang R, et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO Working Group. Lancet Oncol. 2015;16(15):e534\u201342. https:\/\/doi.org\/10.1016\/s1470-2045(15)00088-1.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1225_CR32","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/neuonc\/noad189","volume":"26","author":"PY Wen","year":"2024","unstructured":"Wen PY, van den Bent M, Vogelbaum MA, Chang SM. RANO 2.0: the revised Response Assessment in Neuro-Oncology (RANO) criteria for high- and low-grade glial tumors in adults designed for the future. Neuro Oncol. 2024;26(1):2\u20134. https:\/\/doi.org\/10.1093\/neuonc\/noad189.","journal-title":"Neuro Oncol"},{"issue":"1","key":"1225_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ctrv.2011.06.007","volume":"38","author":"MH Jansen","year":"2012","unstructured":"Jansen MH, van Vuurden DG, Vandertop WP, Kaspers GJ. Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology. Cancer Treat Rev. 2012;38(1):27\u201335. https:\/\/doi.org\/10.1016\/j.ctrv.2011.06.007.","journal-title":"Cancer Treat Rev"},{"issue":"33","key":"1225_CR34","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1200\/jco.23.01059","volume":"41","author":"PY Wen","year":"2023","unstructured":"Wen PY, van den Bent M, Youssef G, et al. RANO 2.0: update to the response assessment in neuro-oncology criteria for high- and low-grade gliomas in adults. J Clin Oncol. 2023;41(33):5187\u201399. https:\/\/doi.org\/10.1200\/jco.23.01059.","journal-title":"J Clin Oncol"},{"issue":"399","key":"1225_CR35","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa0984","volume":"9","author":"DM O'Rourke","year":"2017","unstructured":"O\u2019Rourke DM, Nasrallah MP, Desai A, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017;9(399):eaaa0984. https:\/\/doi.org\/10.1126\/scitranslmed.aaa0984.","journal-title":"Sci Transl Med"},{"issue":"2","key":"1225_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006239","volume":"11","author":"M Zannikou","year":"2023","unstructured":"Zannikou M, Duffy JT, Levine RN, et al. IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM. J Immunother Cancer. 2023;11(2):e006239. https:\/\/doi.org\/10.1136\/jitc-2022-006239.","journal-title":"J Immunother Cancer"},{"issue":"24","key":"1225_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15245852","volume":"15","author":"KD Pawlowski","year":"2023","unstructured":"Pawlowski KD, Duffy JT, Gottschalk S, Balyasnikova IV. Cytokine modification of adoptive chimeric antigen receptor immunotherapy for glioblastoma. Cancers (Basel). 2023;15(24):5852. https:\/\/doi.org\/10.3390\/cancers15245852.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"1225_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-025-05419-w","volume":"176","author":"S Sanikommu","year":"2026","unstructured":"Sanikommu S, Santos AN, Wipplinger C, Dawoud B, Komotar RJ, Lu VM. Patient-reported outcomes as prognostic indicators for overall survival and progression-free survival in brain tumor patients\u2014a systematic review and meta-analysis of randomized clinical trials. J Neurooncol. 2026;176(2):154. https:\/\/doi.org\/10.1007\/s11060-025-05419-w.","journal-title":"J Neurooncol"},{"issue":"2","key":"1225_CR39","doi-asserted-by":"publisher","first-page":"e97","DOI":"10.1016\/s1470-2045(19)30796-x","volume":"21","author":"TS Armstrong","year":"2020","unstructured":"Armstrong TS, Dirven L, Arons D, et al. Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report. Lancet Oncol. 2020;21(2):e97\u2013103. https:\/\/doi.org\/10.1016\/s1470-2045(19)30796-x.","journal-title":"Lancet Oncol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01225-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01225-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01225-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T13:15:19Z","timestamp":1785503719000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-026-01225-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1225"],"URL":"https:\/\/doi.org\/10.1007\/s11523-026-01225-0","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"2 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Sai Sanikommu, Alejandro N. Santos, Bashar Dawoud, Khushi H. Shah, Sima Vazquez, Ashish H. Shah, and Victor M. Lu declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval, Consent to participate, Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":3,"name":"Ethics","label":"Data availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Concept and design: Sai Sanikommu, Victor M. Lu, and Ashish H. Shah; literature review: Sai Sanikommu, Bashar Dawoud, Alejandro N. Santos, Kushi H. Shah, and Sima M. Vazquez; data collection: Sai Sanikommu, Bashar Dawoud, Alejandro N. Santos, Kushi H. Shah, and Sima M. Vazquez; analysis: Sai Sanikommu; writing and editing: Sai Sanikommu, Victor M. Lu, Ashish H. Shah, and Alejandro N. Santos; reviewing: all authors.","order":5,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}